On 7 October, Delhi High Court barred generics manufacturer Glenmark Pharmaceuticals from selling, distributing, marketing and exporting its anti-diabetes drugs Zita and Zitamet. The court found that Glenmark had infringed US-based Merck Sharp & Dohme’s sitagliptin patent used in its anti-diabetes drugs Januvia and Janumet.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
